Aileron Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Rein Therapeutics

12/11/2021 14:12

* Aileron Therapeutics Inc  ALRN.OQ  reported a quarterly
adjusted loss of 7 cents​​ per share for the quarter ended in
September. The mean expectation of three analysts for the
quarter was for a loss of 7 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Aileron Therapeutics Inc's reported EPS for the quarter was a
loss of 7 cents​.
* The mean earnings estimate of analysts was unchanged in the
last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Aileron Therapeutics Inc shares had fallen by 9.3% this
quarter and lost 11.1% so far this year.
* The company reported a quarterly loss of $6.7 million.
* Wall Street's median 12-month price target for Aileron
Therapeutics Inc is $3.50 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 12 at 02:12 p.m.
 ​All figures in US dollars unless otherwise stated